Sana Biotechnology (SANA) Projected to Post Earnings on Monday

Sana Biotechnology (NASDAQ:SANA) is expected to issue its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock opened at $3.36 on Friday. The stock has a market cap of $896.68 million, a price-to-earnings ratio of -3.46 and a beta of 1.96. The stock has a 50 day moving average price of $4.16 and a 200-day moving average price of $4.13. Sana Biotechnology has a one year low of $1.26 and a one year high of $6.55.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of analyst reports. HC Wainwright lowered their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Bank of America increased their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a report on Monday, December 29th. Morgan Stanley reaffirmed an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Friday. Finally, Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Trading of Sana Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC boosted its stake in shares of Sana Biotechnology by 189.4% during the fourth quarter. Virtu Financial LLC now owns 119,312 shares of the company’s stock valued at $486,000 after purchasing an additional 78,088 shares during the period. Invesco Ltd. grew its holdings in shares of Sana Biotechnology by 24.1% in the fourth quarter. Invesco Ltd. now owns 561,835 shares of the company’s stock worth $2,287,000 after purchasing an additional 109,078 shares during the last quarter. XTX Topco Ltd increased its stake in Sana Biotechnology by 9.9% in the 4th quarter. XTX Topco Ltd now owns 117,376 shares of the company’s stock worth $478,000 after buying an additional 10,581 shares during the period. VARCOV Co. bought a new stake in Sana Biotechnology during the 4th quarter valued at about $264,000. Finally, Virtus Investment Advisers LLC lifted its holdings in Sana Biotechnology by 15.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 51,756 shares of the company’s stock valued at $211,000 after buying an additional 6,958 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.